Table 1. Baseline Characteristics and Median List Price, Percentage of Coverage, and Coinsurance Information for Drugs of Interest.

Product	First available year (2010-2019)	Median list price per fill, $a		Coverage, %
		First available year	2019	2010 or year of market entry	Part D plans covering product in 2019	Part D plans requiring coinsurance
						2010 or year of market entry	2019
Tocilizumab, 162 mg/0.9 mL	2015	796	1002	37	37	98	100
Certolizumab pegol
200 mg	2010	1795	4400	67	26	98	100
200 mg/1 mL	2011	1885	4343	64	26	97	100
Etanercept
25 mg	2010	1007	2628	85	73	98	100
50 mg/1 mL	2010	2019	5253	85	73	98	100
Adalimumab
10 mg/0.2 mL	2016	4216	5309	99	100	100	100
20 mg/0.4 mL	2010	1895	5300	45	100	98	100
40 mg/0.8 mL	2010	1890	5254	100	100	98	100
Sarilumab
150 mg/1.14 mL	2018	3157	3385	7	30	100	100
200 mg/1.14 mL	2018	3157	3385	7	30	100	100
Abatacept
125 mg/1 mL	2012	2307	4347	52	39	99	100
50 mg/0.4 mL	2018	4359	4442	42	39	100	100
87.5 mg/0.7 mL	2018	4359	4442	42	39	100	100
Golimumab
100 mg/1 mL	2015	3867	5658	50	30	100	100
50 mg/0.5 mL	2010	2065	4873	51	30	98	100
Tofacitinib
5 mg	2014	2510	4528	39	66	100	100
Extended-release 11 mg	2017	4101	4536	60	62	100	100

^aAll prices were inflation adjusted and are reported in 2019 dollars.